Skip to main content
padlock icon - secure page this page is secure

Effect of the Two Different Leukotriene Receptor Antagonists, Montelukast and Zafirlukast, on Quality of Life: A 12-week Randomized Study

Buy Article:

$36.50 + tax (Refund Policy)

Many studies analyze the effects of many drugs on quality of life (QOL). The aim of this study is to compare the effectiveness of the leukotriene receptor antagonists on QOL. Forty mild asthmatic patients were randomized for 12 treatment-weeks and divided into two groups: the first group was treated with montelukast (MON; 10 mg daily) and the second one was treated with zafirlukast (ZAF; 40 mg daily). All patients underwent clinical examination, spirometry, and completed the Asthma Quality of Life Questionnaire. For each domain, a value of 1 (maximal impairment) and 7 (no impairment) was used. The MON group had in all items a basal median value of 4.7 compared with 5.5 after the treatment (p < 0.05). For physical activities, the mean value was 5.1 compared with 5.9 (p < 0.05). The median scores of 12 symptoms and 5 emotion items were 5.0 and 4.7, significantly lower than 5.7 and 5.3 (p < 0.05). For the environmental stimuli domain, the mean value was 4.6 compared with 5.3 (p < 0.05). The ZAF group had in all items a basal median value of 4.8 compared with 5.7 after the treatment (p < 0.05). For physical activities, the value was 5.0 compared with 5.7 (p < 0.05). Median scores of 12 symptoms and 5 emotions were 4.9 and 4.8, significantly lower than 5.6 and 5.8 (p < 0.05). For the environmental stimuli domain, the median score was 4.7, significantly lower than 5.6 (p < 0.05). The results did not show many differences between the two treatments, showing significant improvement for both MON and ZAF on QOL.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: November 1, 2004

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more